Combination therapy with HDAC and DNMT inhibitors alters the T cell exhaustion state to memory and effector T cell phenotypes [77], suggesting a possible therapeutic option against CTCL. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.